Based on short-term price targets offered by five analysts, the average price target for Gain Therapeutics, Inc. comes to $ The forecasts range from a low. Analyst Forecast. According to 5 analysts, the average rating for GANX stock is "Strong Buy." The month stock price forecast is $, which is an increase of. The 13 analysts offering month price target forecasts for Gain Therapeutics have a median target of , a high estimate of and a low estimate of. Gain Therapeutics (NASDAQ:GANX) Stock, Analyst Ratings, Price Targets, Forecasts. Gain Therapeutics Inc has a consensus price target of $8 based on the ratings. GANX's current price target is $ Learn why top analysts are making this stock forecast for Gain Therapeutics at MarketBeat.
Get Gain Therapeutics Inc (anapa-n.ru) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. The forecasts range from a low of $ to a high of $ A stock's price target is the price at which analysts consider it fairly valued with respect to its. View Gain Therapeutics, Inc. GANX stock quote prices, financial information, real-time forecasts, and company news from CNN. GANXNasdaq Stock Market • NLS real time price • USD. Gain Therapeutics Inc (GANX) Last earnings announcement. 8 Aug Reported EPS. Free Gain Therapeutics (GANX) analysis tools, including analyst ratings and target price forecasts, help you make informed investment decisions. Get Gain Therapeutics Inc (GANX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. ; Volume: K · 65 Day Avg: K ; Day Range ; 52 Week Range View today's Gain Therapeutics Inc stock price and latest GANX news and analysis. Create real-time notifications to follow any changes in the live stock. Earnings report for GANX: Gain Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. Earnings for Gain Therapeutics are expected to decrease in the coming year, from ($) to ($) per share. Price to Earnings Ratio vs. the Market. The P/E. Gain Therapeutics NasdaqGM:GANX Stock Report ; Last Price. US$ ; Market Cap. US$m ; 7D. % ; 1Y. % ; Updated. 18 Aug,
Gain Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. Our. GANX. %. S&P %. Compare To: GANX. Compare. Select to analyze similar companies using key performance metrics; select up to 4 stocks. GANX. Gain. Based on analysts offering 12 month price targets for GANX in the last 3 months. The average price target is $8 with a high estimate of $8 and a low. It currently costs $ to buy one share in Gain Therapeutics Inc. (as of 22/08/ ) which is a change of or % from the last closing price. The Gain Therapeutics, Inc. stock forecast for tomorrow is $ , which would represent a % loss compared to the current price. In the next week, the. Like the earnings yield, which shows the anticipated yield (or return) on a stock based on the earnings and the price paid, the cash yield does the same, but. On average, analysts forecast that GANX's EPS will be -$ for , with the lowest EPS forecast at -$, and the highest EPS forecast at -$ In Gain Therapeutics (GANX) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom. Stock Price Forecast. The 4 analysts with month price forecasts for Gain Therapeutics stock have an average target of , with a low estimate of and a.
The share price as of August 16, is / share. Previously, on August 21, , the share price was / share. This represents a decline of %. Given the current short-term trend, the stock is expected to fall % during the next 3 months and, with a 90% probability hold a price between $ and. Stocks. USA. The RSI of Gain Therapeutics' share price is below 30 at this time. This usually indicates that the stock is becoming oversold or undervalued. Gain Therapeutics (GANX) Forecast. News. EarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest. Latest news for Gain Therapeutics (NASDAQ:GANX). We've gathered opinions of 5 analysts rating GANX stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other.
Find the latest Finch Therapeutics Group, Inc. (FNCH) stock quote, history, news and other vital information to help you with your stock trading and. Analyst. Target Price. ; Earnings. EPS Forecast. Up ; Investor. New Investor. State Street ; Financials. Valuation. High ; Insiders. Largest Buy. Buy K. The price target of $26 was fulfilled within 10 days with a profit of $ (%) receiving and performance score of Average potential price target. GANX Stock, USD %. Gain Therapeutics statistic functions tool In general, we focus on analyzing Gain Stock price patterns and their correlations.